olaparib
Merck Q1 Revenues Increase 50 Percent Driven by Keytruda
The firm's checkpoint inhibitor was once again the primary growth driver, as the drugmaker continues to push the blockbuster into earlier-line treatment settings.
UPenn Researchers Enrolling BRCA1/2 Carriers Into Inovio hTERT Cancer Vaccine study
Research into cancer interception tactics still have a long way to go, but studies like that of Inovio's INO 5401 could offer a framework, a prominent cancer researcher suggested at AACR.
Lynparza Survival Benefit, FDA Approval in Early-Stage Breast Cancer Could Broaden Genetic Testing
Premium
Merck and AstraZeneca's PARP inhibitor led to a survival benefit in early-stage BRCA-mutated breast cancer, potentially necessitating broader early germline testing.
FDA Approves Lynparza as Adjuvant Therapy With Myriad Genetics CDx for BRCA-Mutated Breast Cancer
Updated data from the pivotal OlympiA trial that led the drug's approval shows AstraZeneca and Merck's PARP inhibitor improves survival compared to placebo.
PARP Inhibitors Show Frontline Prostate Cancer Benefit; Conflicting Biomarker Data Raise Questions
Premium
Merck and AstraZeneca's Lynparza benefited patients regardless of HRR gene mutation status, while Janssen's niraparib only benefited a biomarker-defined group.